Marshall Wace’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Marshall Wace’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-84,508	Closed	-$8.62M	–	2833
2023 Q2	$8.62M	Sell	84,508 -330,446	-80%	-$31.3M	0.02%	802
2023 Q1	$37.7M	Buy	414,954 +209,612	+102%	+$12.3M	0.08%	279
2022 Q4	$7.8M	Buy	205,342 +193,342	+1,611%	+$6.65M	0.02%	939
2022 Q3	$302K	Buy	+12,000	New	+$333K	﹤0.01%	2951
2021 Q1	–	Sell	-10,516	Closed	-$1.3M	–	2966
2020 Q4	$1.3M	Buy	10,516 +3,591	+52%	+$472K	0.01%	1109
2020 Q3	$675K	Buy	+6,925	New	+$865K	﹤0.01%	1154
2018 Q2	–	Sell	-10,600	Closed	-$217K	–	882
2018 Q1	$217K	Buy	+10,600	New	+$273K	0.01%	512

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's RETA Position: Q3 2023 in Review

Marshall Wace sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 84,508 shares — an estimated $8.62M sold.

Marshall Wace first reported a position in RETA in Q1 2018 and held it in 7 quarters. The position peaked at $37.7M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Marshall Wace reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Marshall Wace sold 84,508 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $8.62M.
Marshall Wace first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 7 quarters.
Marshall Wace's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $37.7M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Marshall Wace's 13F filing for Q3 2023, filed 14 Nov 2023.